Patents by Inventor Juerg Gertsch

Juerg Gertsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CB2 receptor ligands for the treatment of psychiatric disorders
    Patent number: 10016373
    Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 10, 2018
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch
  • TREATMENT OF SCHIZOPHRENIA USING BETA-CARYOPHYLLENE AND CB2 RECEPTOR AGONISTS
    Publication number: 20170151182
    Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 1, 2017
    Applicant: ARIEL SCIENTIFIC INNOVATIONS LTD
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch
  • CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20170042832
    Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Applicant: ARIEL - UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY, LTD.
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch
  • CB2 receptor ligands for the treatment of psychiatric disorders
    Patent number: 9486419
    Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 8, 2016
    Assignee: Ariel-University Research and Development Company
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch
  • CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20160089349
    Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 31, 2016
    Inventors: Sharon ANAVI-GOFFER, Juerg GERTSCH
  • TREATMENT OF SCHIZOPHRENIA USING BETA-CARYOPHYLLENE AND CB2 RECEPTOR AGONISTS
    Publication number: 20150051299
    Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Inventors: Sharon Anavi-Goffer, Juerg Gertsch